Prevalence of Small Intestinal Bacterial Overgrowth Syndrome in Patients with Irritable Bowel Syndrome who Have Suffered COVID-19
https://doi.org/10.22416/1382-4376-2022-32-3-35-39
Abstract
Aim. To study the prevalence of the small intestinal bacterial overgrowth syndrome in patients with irritable bowel syndrome with diarrhea who have had COVID-19 infection.
Materials and methods. 60 patients with irritable bowel syndrome with diarrhea were examined. In 30 patients, irritable bowel syndrome was diagnosed after COVID-19 infection (main group). The comparison group consisted of 30 patients with classical stress-induced irritable bowel syndrome. The small intestinal bacterial overgrowth syndrome was diagnosed using a hydrogen breath test with lactulose loading in all patients.
Results. In main group the small intestinal bacterial overgrowth syndrome was diagnosed in 93.3 % patients, which was statistically significantly higher (p < 0.01) relative to the comparison group — 60.0 % patients
Conclusion. Irritable bowel syndrome in patients who have undergone COVID-19 occurs against the background of the small intestinal bacterial overgrowth syndrome development.
Keywords
Supporting agencies: нет
About the Authors
A. V. Nalyotov
M. Gorky Donetsk National Medical University
Russian Federation
Russian Federation
Andrew V. Nalyotov — Dr. Sci. (Med.), Prof., Head of Department of Pediatrics No. 2
83003, Donetsk People`s Republic, Donetsk, Illich avе., 16
N. P. Guz
Medical Centre “Gastro-line”
Natalya P. Guz — director
83003, Donetsk People`s Republic, Donetsk, Illich avе., 14E
References
1. Lacy В.Е., Mearin F., Chang L., Chey W.D., Lembo A.J., Simren M., et al. Bowel Disorders. Gastroenterology. 2016;150:1393–407. DOI: 10.1053/j.gastro.2016.02.031
2. Ivashkin V.T., Shelygin Ju.A., Baranskaja E.K., Belousova E.A., Beniashvili A.G., Vasil'ev S.V., et al. Diagnosis and treatment of the irritable bowel syndrome: clinical guidelines of the Russian gastroenterological association and Russian association of coloproctology. Rus J Gastroenterol Hepatol Coloproctol. 2017;27(5):76–93 (In Russ.). DOI: 10.22416/1382-4376-2017-27-5-76-93
3. Canavan C., West J., Card T. The epidemiology of irritable bowel syndrome. Clin. Epidemiol. 2014;6:71–80. DOI: 10.2147/CLEP.S40245
4. Naletov A.V., Masjuta D.I., Chalaja L.F. Pathogenetic basis of irritable bowel syndrome in patients who have undergone COVID-19. Mother and Baby in Kuzbass. 2021;4(87):12–16 (In Russ.).
5. Ivashkin V.T., Zolnikova O.Yu. Irritable Bowel Syndrome in Terms of Changes in the Microbiota. Rus J Gastroenterol Hepatol Coloproctol. 2019;29(1):68–76 (In Russ.). DOI: 10.22416/1382-4376-2019-29-1-84-92
6. Sakhautdinova G.M., Nagaeva R.R., Asanbaeva K.E. The modern ideas about the etiology of ir ritable bowel syndrome. Medical Council. 2019;3:152–5 (In Russ.). DOI: 10.21518/2079-701X-2019-3-152-155
7. Krogsgaard L.R., Andersen L.O., Johannesen T.B., Engsbro A.L., Stensvold C.R., Nielsen H.V., et al. Characteristics of the bacterial microbiome in association with common intestinal parasites in irritable bowel syndrome. Clin Transl Gastroenterol. 2018;9(6):161. DOI: 10.1038/s41424-018-0027-2
8. Kovaleva A.L., Poluektova E.A., Shifrin O.S. Intestinal Barrier, Permeability and Nonspecific Inflammation in Functional Gastrointestinal Disorders. Rus J Gastroenterol Hepatol Coloproctol. 2020;30(4):52–9 (In Russ.). DOI: 10.22416/1382-4376-2020-30-4-52-59
9. Ghoshal U.C., Srivastava D. Irritable bowel syndrome and small intestinal bacterial overgrowth: Meaningful association or unnecessary hype. World J Gastroenterol. 2014;20(10):2482–91. DOI: 10.3748/wjg.v20.i10.2482
10. Rao S.S.C., Bhagatwala J. Small intestinal bacterial overgrowth: clinical features and therapeutic management. Clin Transl Gastroenterol. 2019;10(10):e00078. DOI: 10.14309/ctg.0000000000000078
11. Ivashkin V.T., Sheptulin A.A., Zolnikova O.Yu., Okhlobystin A.V., Poluektova E.A., Trukhmanov A.S., et al. New Coronavirus Infection (COVID-19) and Digestive System. Rus J Gastroenterol Hepatol Coloproctol. 2020;30(3): 7–13 (In Russ.). DOI: 10.22416/1382-4376-2020-30-3-7
12. Oshima T., Siah K.T.H., Yoshimoto T., Miura K., Tomita T., Fukui H., et al. Impacts of the COVID-19 pandemic on functional dyspepsia and irritable bowel syndrome: A population-based survey. J Gastroenterol Hepatol. 2021;36(7):1820–7. DOI: 10.1111/jgh.15346
13. Ivashkin V.T., Maev I.V., Shelygin Ju.A., Baranskaja E.K., Belous S.S., Belousova E.A., et al. Diagnosis and treatment of irritable bowel syndrome (Clinical recommendations of the Russian Gastroenterological Association and the Association of Coloproctologists of Russia). Rus J Gastrojenterol Hepatol Coloproctol. 2021;31(5):74–95 (In Russ.). DOI: 10.22416/1382-4376-2021-31-5-74-95
Supplementary files
Review
For citations:
Nalyotov A.V., Guz N.P. Prevalence of Small Intestinal Bacterial Overgrowth Syndrome in Patients with Irritable Bowel Syndrome who Have Suffered COVID-19. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(3):35-39. https://doi.org/10.22416/1382-4376-2022-32-3-35-39
Views:
915
Email this article 
